Feature | June 05, 2014

FFR Remains Gold Standard in Determining Severity of Coronary Artery Blockages

VERIFY-2 study finds two new coronary lesion assessment measures do not provide sufficient accuracy

June 5, 2014 — New measures of the severity of coronary artery blockages do not provide enough accuracy to guide treatment decisions, according to the results of the VERIFY-2 study presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2014 scientific sessions in Las Vegas.

To aid decisions before performing percutaneous coronary intervention (PCI), interventional cardiologists can use several types of assessments that measure whether a blockage in the coronary artery is limiting blood flow to the heart. Fractional flow reserve (FFR) is a validated technique that measures pressure differences across the blockage. FFR-guided PCI improves outcomes compared to angiography alone. However, some interventional cardiologists have been hesitant to use FFR because it requires administration of the drug adenosine, which may not be well tolerated in some patients and adds time to the procedure.

Instantaneous wave-free ratio (iFR) is a new measure that assesses the pressure difference across a stenosis during a specific period of the cardiac cycle. It is measured at rest and does not require the administration of adenosine. Another index of stenosis severity, Pd/Pa, is also measured at rest and without adenosine, but unlike iFR, it does not require any specific measurement software. The previous VERIFY and RESOLVE studies indicated that both iFR and Pd/Pa have similar levels of diagnostic accuracy (about 80 percent) when compared to FFR. The recent ADVISE II study demonstrated that a hybrid strategy using a combination of iFR and FFR correctly classified 94 percent of lesions compared to a strategy of using FFR in all patients, while avoiding the use of adenosine in two-thirds of the patients in the study.

“The measurement of iFR has recently been introduced to aid interventional cardiologists in their assessment of coronary lesions without the need for adenosine,” said Stuart Watkins, M.D., consultant cardiologist at the Golden Jubilee National Hospital in Glasgow, Scotland.“VERIFY-2 was designed to evaluate the accuracy of this measurement compared to Pd/Pa using FFR as the currently accepted gold standard.”

In the study presented at SCAI, researchers examined two hybrid assessment strategies: iFR-FFR with an adenosine-zone of 0.86-0.93, and Pd/Pa-FFR with an adenosine-zone of 0.87-0.94. A total of 97 patients with 120 coronary artery blockages were assessed.

They found 10.1 percent of lesions were misclassified using iFR-FFR, compared to 6.3 percent using Pd/Pa-FFR.

Next, they compared the accuracy of iFR and Pd/Pa compared to FFR using binary cut-off values of 0.90 for iFR and 0.92 for Pd/Pa. In this analysis, the use of iFR alone would result in inappropriate PCI in 8.3 percent of lesions and incomplete revascularization in another 10 percent. Using Pd/Pa alone would result in inappropriate PCI in 4.2 percent of lesions and incomplete revascularization in another 10.8 percent.

Researchers concluded that both hybrid decision-making strategies and the use of binary cut-off values resulted in similar levels of lesion misclassification compared to FFR.

“FFR remains the gold standard – we have concluded neither iFR nor Pd/Pa is sufficiently accurate to guide decisions on the need for revascularization,” said Watkins. “Although these measures aren’t accurate enough to replace FFR, this study adds to our body of knowledge as we work to identify the most effective ways to measure lesion severity.”

Watkins reported no disclosures. The title of the presentation was “Comparison of Lesion Level Decision Making in the Cath Lab Using Hyperemic and Non-hyperemic Pressure Wire Derived Indices of Stenosis Severity: The VERIFY-2 Study.”

For more information: www.scai.org

Related Content

LimFlow System, critical limb ischemia, CLI, CE Mark
News | Stents Peripheral| December 08, 2016
LimFlow SA announced in November that it received the CE Mark for its fully percutaneous LimFlow System designed for...
St. Jude Medical, HeartMate 3 LVAS, MOMENTUM 3 IDE study results, AHA Scientific Sessions 2016
News | Ventricular Assist Devices (VAD)| December 08, 2016
St. Jude Medical Inc. announced results of the MOMENTUM 3 U.S. IDE Clinical Study during a late-breaking clinical trial...
Sponsored Content | Videos | Angiography| December 07, 2016
Shimadzu's latest generation interventional lab angiography imaging system, the Trinias, enables advanced imaging cap
Lotus Edge valve
News | Heart Valve Technology| December 07, 2016
December 7, 2016 — Boston Scientific announced a definitive agreement to acquire certain manufacturing assets and cap
Impella CP, Abiomed
News | Hemodynamic Support Devices| December 07, 2016
December 7, 2016 — Abiomed Inc. announced it has expanded its U.S.
Vascular Solutions, Teleflex
Feature | December 07, 2016
December 7, 2016 — Teleflex Inc. and Vascular Solutions Inc.
Siemens Healthineers, PURE Platform, angiography, EVAR, CTO, RSNA 2016
News | Angiography| December 07, 2016
December 7, 2016 — At the 102nd Scientific Assembly and Annual Meeting of the Radiological Society of North America (
Spectranetics, Stellarex 0.014-inch DCB, CE Mark
News | Drug-Eluting Balloons| December 06, 2016
December 6, 2016 — The Spectranetics Corp.
PET, F-18 florbetaben, cardiac amyloidosis, Princess Alexandria Hospital

In a pilot study, F-18-florbetaben PET imaging appeared promising for differentiating between cardiac amyloidosis and hypertensive heart disease. Image courtesy of W. Phillip Law/Princess Alexandra Hospital, Brisbane, Australia.

News | Nuclear Imaging| December 06, 2016
Researchers at Princess Alexandra Hospital, Brisbane, Australia, have demonstrated that cardiac amyloidosis (abnormal...
TCT 2016, TCT.16, main arena, late breaking trials, transcatheter cardiovascular therapeutics

There were several hot topics that came out of the 2016 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting Oct. 29 - Nov. 2, which made this month's top 20 list, including several videos. Number 4 on the list of content was the result of the EXCEL Trial key TCT late-breaker, which showed stenting is equal in outcomes to surgery for the first time, when using one of the latest generation drug-eluting stents. 

Feature | December 05, 2016
December 5, 2016 — Here is the list of the top 20 most popular pieces of content on the Diagnostic and Interventional
Overlay Init